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Park et al General Thoracic Surgerymanner, the added cost may be justified by all the attendant
benefits over traditional open surgery.
Robotic lobectomy is a feasible, safe, and oncologically
sound surgical treatment for early-stage lung cancer. The
technique is reproducible across multiple centers and yields
results consistent with the best seen with conventional
VATS. It should not be considered experimental, but an ac-
cepted minimally invasive thoracic surgical technique. Fu-
ture evaluation of differences between robotic versus
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Dr Thomas A. D’Amico (Durham, NC). Robotics has been
used in numerous surgical procedures, but, with few exceptions,
this technologic advance has not translated into improved out-
comes. Many robotic applications have been unveiled as the man-
ifestation of a tool—sometimes a marketing tool—in search of an
application. The principal advantages of robotic assistance in sur-
gery are the greater degree of instrumental articulation and motion
scaling. However, despite these recognized technical advantages,
the demonstration of superior outcomes has been disappointing.
As well, several disadvantages of the robotic system have been
proven, including the lack of tactile feedback, personnel commit-
ment, cost of the robot and its instruments, and the length of the
procedures. In addition, the instrumentation that is currently avail-
able for use robotically is still limited.
The multi-institutional retrospective review by Park and his col-
leagues represents the largest robotic lobectomy series to date;
more than 325 consecutive patients underwent robotic lobectomy
for early-stage disease at the 3 institutions. The conversion rate
was, admirably, relatively low, only 8%, with reasonable morbid-
ity, consistent with thoracoscopic lobectomy series in the litera-
ture. The length of stay was longer, perhaps with the inclusion
of patients in Europe. Finally, stage-specific survival was excel-
lent, also consistent with both open and thoracoscopic experiences,
including patients with stage IIIA disease. Thus, the authors have
demonstrated that robotic lobectomy for early-stage disease is ef-
fective, feasible, oncologically sound, and comparable, but not su-
perior, to thoracoscopic lobectomy.
Less clear is the compared effectiveness of the robot vis-a-vis
thoracoscopic lobectomy. Although thoracoscopic lobectomy has
been demonstrated to be superior to open lobectomy in terms of
outcomes and costs, analyses of the costs relating to robotic lobec-
tomy suggest that the procedure is approximately $2000 more ex-
pensive than open and $4000 more expensive than VATS. In light
of these issues, I have 3 questions, and I will ask them 1 at a time.
How should the cost of robotic lobectomy be considered in the
evaluation of its effectiveness? Unlike some technologies in which
cost has decreased over the evolution of the technology, the oppo-
site seems to be happening with robotics; costs continue to in-
crease, both fixed and variable. Although the promise that this
technology as the future of all surgery has been adamantly put for-
ward by others, I believe that a more logical response is required to
adequately assess the effectiveness of robotic lobectomy.
Dr Park. Thank you for that analysis and question.
Cost is an extremely important feature, and you are right, robot-
ics is a technology. I think it is critical to compare robotics (a min-
imally invasive modality) to thoracotomy, which is still the
standard approach throughout the world. You stated that studies
have shown that robotics is more expensive than thoracotomy,
but I think that does remain to be seen and proven. We are going
to be presenting a paper at the meeting of The International Society
for Minimally Invasive Cardiothoracic Surgery (ISMICS) next
month that compares costs associated with VATS versus robotic
versus thoracotomy, which I believe will begin to address this. Irdiovascular Surgery c Volume 143, Number 2 387
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from thoracotomy to minimally invasive approaches to early-stage
lung cancer in the appropriate patients? Therefore, any cost anal-
ysis has to take that into account. If you are able to transition more
surgeons into doing oncologically sound and safe procedures min-
imally invasively through the use of robotic technology, then per-
haps those costs are justified. However, all things being
considered, I think if you were to compare VATS nonrobotic and
robotic in the most excellent hands, then yes, there’s no question
that robotics is more expensive. Whether that cost is justified de-
pends on whether we could have most of our thoracic surgeons
or people who do thoracic surgery do it by VATS.
Dr D’Amico. The issue of the transition brings up my second
question. Inasmuch as thoracic surgeons, both in and out of train-
ing, are not adequately exposed to robotics, howdoyou recommend
that surgeons take on this new technology to assure competency?
Dr Park. That question is in parallel to questions about ad-
vancedminimally invasive surgery in general. Atmost of our excel-
lent training programs, the trainees are getting more and more
exposed to advanced minimally invasive surgery, but that still
leaves a whole population of surgeons who only know how to do
thoracotomies, and they are faced with the same challenge of hav-
ing to figure out how to do advancedVATS surgery, let alone robotic
surgery. I think it is incumbent on major organizations, like The
American Association for Thoracic Surgery and The Society of
Thoracic Surgeons, to come up with guidelines for defining the ap-
propriate use of such technologies and the minimum credentialing
so that surgeons can get trained and be deemed to be qualified in
these procedures. We need the organizations to come forth and de-
finewhat the procedures are, to define how people can get trained in
those procedures, and then to allow hospitals throughout the coun-
try and the world to determine how they can credential their sur-
geons and deem that they are qualified to do these procedures.
Dr D’Amico. I do not have an answer to my own question, but
surgical associations have never done that for any other procedure,
so I do not see The American Association for Thoracic Surgery or
The Society of Thoracic Surgeons or the Board coming up and say-
ing: This is how you need to do it. It is going to have to come from
somewhere, but I would not necessarily expect that the associa-
tions would do it.
Finally, please comment on the impact of new robotic technol-
ogy that is on the frontier: single-port entry, new energy sources,
in-line staplers, infrared optics for sentinel node technology, sim-
ulation programs, and others. How do you think these new ad-
vances will translate into improved effectiveness for lobectomy?
Dr Park. I think simulation, as you mentioned, is one of the
critical new technologies that is going to allow trainees or anybody
who is established who wants to learn this technology and ad-
vanced minimally invasive techniques to do this in a more safe en-
vironment, to get practice without putting patients at harm. There
is going to be stapling technology to allow direct control of the sta-
pler. I think using the 3-dimensional optics is going to be a huge
benefit, because even with some of the newer-technology staplers,
most of us still feel some trepidation passing the staplers behind
the hilar structures, and I think that is only going to help. Certainly,
other instrumentation to help with retraction, exposure, and suc-
tioning will all help. However, as you alluded to before, they are
going to potentially result in increased costs. I think we have to388 The Journal of Thoracic and Cardiovascular Surgevaluate these critically and decide which are necessary, and that
will make these procedures safer and more feasible.
Dr Scott J. Swanson (Boston, Mass). What I would like to do
now is just put on your hat of senior lung cancer surgeon. With the
lung cancer screening trial coming and the fact that VATS lobec-
tomies have gone from about 10% to 30%, how would you use
this technology across the country? Do you think it is realistic
that all hospitals should have a robot and everyone should learn
it? Should there be centers where people go for robotic surgery?
How realistically should we get more minimally invasive opera-
tions to our patients?
Dr Park. We have to remember that the 30% number is from
The Society of Thoracic Surgeons voluntary database. There are
other nonvoluntary databases that show that some rates of VATS
lobectomy are as low as 6%. I am not sure that we are seeing an
explosion of VATS lobectomy as a technique. I would love to think
that that is true.
Your question is very similar to Dr D’Amico’s.
As with any other technology, we need to identify centers of ex-
cellence and concentrate on trying to bring people to see what is
going on in those centers, to organize training courses so that peo-
ple can gain exposure to minimally invasive techniques and decide
for themselves whether they are reasonable options and whether
they do fit with their armamentarium. With increasing early-stage
disease, increasing minimally invasive approaches is warranted
and necessary, not only for the benefit of the hospital but for the
benefit of the health care system in general in terms of allowing pa-
tients to recover quicker, getting them out of the hospital, and get-
ting them back to their preoperative state.
DrK. AdamLee (Cherry Hill, NJ). In your data did you see any
difference between a 3-arm approach and a 4-arm approach?
Looking forward, do you see the robotic assisted technique transi-
tioning an open thoracotomy surgeon to become more involved in
minimally invasive surgery? Do you see some of those positive re-
sults of the robotics procedure helping to reach that goal?
Dr Park. There was no real difference between 3-arm and
4-arm techniques. Again, 2 of the centers had a 4-arm technique
and 1 had a 3-arm technique, but basically there was just 1 addi-
tional incision. All of the unified themes of non–rib-spreading
and using videoscopic guidance were the same. There was no
real difference clinically.
It is really hard to know whether robotics can help traditional
thoracotomy surgeons transition to minimally invasive. I think
we have to study that, if it is feasible, prospectively. I know, again,
that VATS lobectomy and the excellent results that are published
are being done so by essentially a core group of outstanding prac-
titioners at great centers. The question is not whether robotics is
the answer as opposed to VATS; the question is how we can appro-
priately use technology to increase the percentage of minimally in-
vasive procedures that are done appropriately.
Dr Todd L. Demmy (Buffalo, NY). Another surgeon who per-
formed many robotic lobectomies commented that a large tumor
in the upper lobe is a hassle, and this gets to the issuewith the robot
having just 1 implementing arm per port. With thoracoscopy, you
can use multiple retractors from a single port and handle that large
tumor. In your study, did you notice any effect of big tumors in the
upper lobe? You had a 10-cm specimen. Was that in the lower
lobe?ery c February 2012
Park et al General Thoracic SurgeryDr Park.All of the techniques had a utility incision and most of
the assistants were able to retract through the utility incision. I am
aware of no increased difficulty with larger tumors in these robotic
series.
Dr Joachim Schirren (Wiesbaden, Germany). The patients in
stage IA and 1B are nearly cured, but in stage II, you have resultsThe Journal of Thoracic and Cayou can reach in open surgery in stage III. Therefore, my question
is how many systemic relapses did you have and how many local
relapses did you find in this stage?
Dr Park. Only 9 of the 32 patients had local-only relapse, and
the majority of the 32 patients had either local plus distant or dis-
tant relapse. It was really systemic recurrence.rdiovascular Surgery c Volume 143, Number 2 389
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